💨 Abstract

The European Medicines Agency (EMA) has approved the use of an AI tool, AIM-NASH, in clinical trials to identify the severity of a type of fatty liver disease, metabolic dysfunction-associated steatohepatitis (MASH). The AI tool, which has less variability than the current standard, will help researchers gather clearer evidence on the benefits of new treatments in trials.

Courtesy: theprint.in

Summarized by Einstein Beta 🤖